metyrapone and Nelson Syndrome

metyrapone has been researched along with Nelson Syndrome in 8 studies

Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.
metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.

Nelson Syndrome: A syndrome characterized by HYPERPIGMENTATION, enlarging pituitary mass, visual defects secondary to compression of the OPTIC CHIASM, and elevated serum ACTH. It is caused by the expansion of an underlying ACTH-SECRETING PITUITARY ADENOMA that grows in the absence of feedback inhibition by adrenal CORTICOSTEROIDS, usually after ADRENALECTOMY.

Research

Studies (8)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Number of Participants That Experience Changes in Clinical Signs of Hypercortisolemia

The number of participants that achieved a urinary free cortisol level above the upper limit of the normal range but reduced by ≥50% from baseline at week 4. (NCT02160730)
Timeframe: Baseline, Week 4

Number of Participants That Have a Visible Change in Tumor Size

A visible change in tumor size as determined by the investigator after reviewing MRI reports between baseline and 4 weeks of treatment. (NCT02160730)
Timeframe: Baseline, 4 weeks

Number of Participants With a Normalized 24 Hour Urinary Free Cortisol After 4 Weeks

"To evaluate the efficacy of R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks on normalizing 24 hour urinary free cortisol (24 h UFC) levels in CD patients. Normalizing is defined as having urine free cortisol levels within the normal range for that lab value." (NCT02160730)
Timeframe: Baseline, 4 weeks

Number of Participants With Adverse Events

The number of participants that experience an adverse event between baseline and study end likely related to study drug as a measure of safety and tolerability. (NCT02160730)
Timeframe: Baseline, 4 weeks

Change in Clinical Symptoms

Change in typical Cushing's syndrome clinical signs and symptoms defined by mean weight at baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks

Change in Diastolic Blood Pressure

Mean diastolic blood pressure between baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks

Change in Mean HbA1c Levels Between Baseline and 4 Weeks

HbA1c levels are measured at baseline and at study end, these are averaged across all subjects. (NCT02160730)
Timeframe: Baseline, 4 Weeks

Change in Systolic Blood Pressure

Mean change in systolic blood pressure between baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks

Changes in Serum Cortisol Between Baseline and 4 Weeks

Mean serum cortisol values at baseline and 4 weeks (NCT02160730)
Timeframe: Baseline, 4 weeks

Fasting Glucose at Baseline and 4 Weeks

Mean change between baseline and week 4 of fasting blood glucose levels. (NCT02160730)
Timeframe: Baseline, 4 Weeks

Plasma ACTH at Baseline and 4 Weeks

Mean change in Plasma ACTH between baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks

Reviews

2 reviews available for metyrapone and Nelson Syndrome

Trials

1 trial available for metyrapone and Nelson Syndrome

Other Studies

5 other studies available for metyrapone and Nelson Syndrome